Veracyte, Inc. — FY 2013 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2013; quarterly figures below include the three months ended December 31, 2013. Veracyte is an early-stage molecular diagnostics company whose revenue came entirely from Afirma, a thyroid nodule diagnostic solution. Its Gene Expression Classifier is intended to help identify benign nodules among indeterminate cytology results and reduce unnecessary surgery.
Financial performance and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $21.9 million | $11.6 million |
| Cost of revenue | $12.6 million | $7.6 million |
| Gross profit and margin | $9.3 million; 42.4% | $4.0 million; 34.8% |
| Operating expenses | $45.1 million | $30.6 million |
| Operating loss | $(23.2) million | $(18.9) million |
| Net loss | $(25.6) million | $(18.6) million |
| Net loss per share, basic and diluted | $(6.15) | $(28.68) |
| Cash used in operating activities | $19.2 million | $7.2 million |
Fourth quarter: Revenue was $6.8 million versus $4.5 million in Q4 2012. Net loss was $5.9 million versus $4.8 million. Quarterly EPS was $(0.42) versus $(7.27); the substantial change in weighted-average shares following the IPO makes per-share comparisons less informative.
- FY revenue increased 88%, reflecting higher commercial reimbursement and collections and increased Afirma adoption. FNA samples received rose 92% to 49,670.
- Operating expenses rose 47%; selling and marketing increased 48%, including higher Genzyme co-promotion costs, while general and administrative expense increased 53%, partly reflecting IPO-related professional fees and public-company costs.
- Cash and cash equivalents were $71.2 million at year-end, up from $14.0 million; working capital was $61.0 million. The company reported total assets of $79.6 million and stockholders’ equity of $56.4 million.
- Debt had a $4.9 million net carrying value at year-end; the original $5.0 million term loan bears 6.06% interest and is secured by substantially all assets other than intellectual property and certain other assets. An additional loan of up to $5.0 million was available subject to the agreement’s terms.
Changes, outlook, risks, and notable items
- The November 2013 IPO generated approximately $59.2 million in net proceeds. Preferred stock converted into common stock upon completion of the IPO.
- Management expected operating losses to continue in the near term and anticipated increased research and development, selling and marketing, and general and administrative expenses. It stated that year-end cash and expected Afirma revenue should fund anticipated needs for at least 12 months, based on its current plan. No numeric revenue or earnings guidance was provided.
- Management planned to introduce Afirma Malignancy Classifiers in Q2 2014 and targeted commercialization of an interstitial lung disease product in 2016; both plans were subject to development and validation risks.
- Revenue recognition is notably collection-dependent: for many payers, revenue is recognized only when payment is reported or cash is received. At year-end, $40.9 million of cumulative billed amounts for processed tests had not met revenue-recognition criteria and remained unpaid; collection timing and ultimate recovery were uncertain. This amount is not reported revenue or accounts receivable.
- Medicare, UnitedHealthcare, and Aetna accounted for 59% of FY 2013 revenue combined (32%, 18%, and 9%, respectively). The company cited reimbursement uncertainty, claims delays, and payer concentration as material risks.
- Genzyme co-promotion fees were 40% of Afirma cash receipts in 2013 and were scheduled to decline to 32% on March 1, 2014. FY 2013 included a $2.1 million expense from remeasurement of a preferred-stock liability, which was settled in 2013 and will not recur in that form.
- Other key risks include potential FDA oversight of laboratory-developed tests, reliance on sole-source suppliers and TCP for cytopathology services, product-development execution, and ongoing losses. No material legal proceedings were pending. The auditor issued an unqualified opinion; management reported disclosure controls were effective at the reasonable-assurance level.
Investor verification priorities
- Track cash collections, denials, and aging of the $40.9 million in billed but unrecognized amounts, and distinguish these from recognized revenue and receivables.
- Verify Afirma volume growth, reimbursement rates, payer coverage, and the effect of payer concentration on revenue and cash flow.
- Assess whether improving gross margin can offset rising operating expenses and ongoing operating losses.
- Confirm the remaining debt balance, loan covenants, repayment schedule, and whether the additional facility was drawn.
- Monitor launch timing, clinical evidence, reimbursement, and commercial uptake for the planned classifiers and lung program.
- Review dilution from equity compensation and potential share sales following the IPO lock-up expiration.